Pharmacokinetic Study of Fondaparinux in Outpatients With Renal Dysfunction

Studies of Fondaparinux in Patients With Renal Dysfunction: PK Study of Fondaparinux in Outpatients With Renal Dysfunction

Status

Withdrawn

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00483600

Enrollment

Registered

2007-06-07

Start date

2007-08-31

Completion date

2008-08-31

Last updated

2014-07-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Kidney Diseases

Keywords

Fondaparinux, Pharmacokinetic

Brief summary

To determine the appropriate dose and safety of a preventative dose of fondaparinux, an anticoagulant medication (blood thinner) in patients with kidney disease.

Detailed description

This study will evaluate the PK of fondaparinux in patients who have renal insufficiency. Fondaparinux is cleared from the body mainly by the kidneys. Therefore in patients with kidney diseases, full doses of fondaparinux could cause bleeding problems. The correct dose of fondaparinux that should be used in patients with kidney disease is not known. The purpose of this research is to determine the PK and safety of a preventative dose (2.5mg subcutaneously every other day) of fondaparinux for patients with kidney disease.

Interventions

DRUGfondaparinux

injections of 2.5mg every other day for 4 weeks

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

BASIC_SCIENCE

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Outpatients in the Medicine and Nephrology clinics who are 18 years or older, * Outpatients in the Medicine and Nephrology clinics who have an estimated creatinine clearances between 20-30ml/min, * Outpatients in the Medicine and Nephrology clinics who are able to give consent will be included.

Exclusion criteria

* anticoagulation therapy for thrombosis or other indication * pregnant or breast-feeding * hypersensitivity to fondaparinux * subjects also will be excluded if there is concern for an increased risk of bleeding which includes the following: * known bleeding disorder (see Section 8. Hemostatic Assessment) * blood transfusion in the past 3 months * acute ulcer disease with past 3 months * platelet count \< 120,000 mm3 * prolonged baseline prothrombin time (PT) or activated partial thromboplastin time (aPTT) above upper limit of normal laboratory range * major trauma or surgery within two weeks prior to enrollment * history of intracranial hemorrhage

Design outcomes

Primary

Measure	Time frame
PK parameters (half-life, area-under-the curve, and peak serum concentration)	after day 7 and after day 27

Secondary

Measure	Time frame
Anti-factor Xa levels and assessment for bleeding(complete blood count)	days 3, 13 and 19

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026